VYNE (VYNE Therapeutics) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VYNE VYNE Therapeutics Inc VYNE
59 GF Score
Price $27.86
GF Value $29.38
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is VYNE Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

VYNE
59GF Score
VYNE Therapeutics Inc VYNE
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is VYNE Therapeutics (VYNE) Overvalued in 2026?

Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be undervalued. The current stock price of $27.86 is trading 5.2% below its estimated GF Value™ of $29.38. GuruFocus considers VYNE Therapeutics to be Fairly Valued.

Key valuation signals for VYNE:

  • Short Ratio:
  • GF Value™: $29.38 vs. price of $27.86 (5.2% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VYNE Therapeutics Business Description

Address P.O. Box 125, Stewartsville, NJ, USA, 08886
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
59GF Score

Get the complete analysis for VYNE

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.86
Price
$29.38
GF Value